Trial of Pimavanserin in Dementia-Related Psychosis.

  title={Trial of Pimavanserin in Dementia-Related Psychosis.},
  author={Pierre N. Tariot and Jeffrey L. Cummings and Maria Soto-martin and Clive Ballard and Deniz Erten‐Lyons and David L. Sultzer and Davangere P. Devanand and Daniel Weintraub and Bradley W. McEvoy and James M. Youakim and Srdjan Stankovic and Erin Pennock Foff},
  journal={The New England journal of medicine},
  volume={385 4},
BACKGROUND Patients with dementia due to neurodegenerative disease can have dementia-related psychosis. The effects of the oral 5-HT2A inverse agonist and antagonist pimavanserin on psychosis related to various causes of dementia are not clear. METHODS We conducted a phase 3, double-blind, randomized, placebo-controlled discontinuation trial involving patients with psychosis related to Alzheimer's disease, Parkinson's disease dementia, dementia with Lewy bodies, frontotemporal dementia, or… 
Advances in dementia with Lewy bodies
  • M. Armstrong
  • Medicine, Psychology
    Therapeutic advances in neurological disorders
  • 2021
Recent advances in dementia with Lewy bodies include publication of updated diagnostic criteria and recognition of prodromal DLB states, including mild cognitive impairment, delirium-onet, and psychiatric-onset forms.
Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
Aducanumab, a monoclonal antibody recently approved by the Food and Drug Administration, was able to reduce Aβ accumulation and slow the progression of cognitive impairment, and was claimed to have an effect on the second hallmark of AD, decreasing the level of phospho-Tau evaluated in cerebrospinal fluid and by positron emission tomography.
Executive Summary of the 2021 International Conference of Korean Dementia Association: A Report From the Academic Committee of the Korean Dementia Association
Through the second international conference of the Korean Dementia Association (KDA), researchers from all over the world have participated in the exchange of opinions with KDA members on the most up-to-date topics and this will be an important milestone to widen the latest knowledge in the research of AD’s diagnosis, therapeutics, pathogenesis.
Long-term outcomes with pimavanserin for psychosis in clinical practice
The role of basket trials in drug development for neurodegenerative disorders
Basket trials may increase drug development efficiency by reducing redundancy in trial implementation, enhancing recruitment, sharing placebo groups, and using biomarkers relevant to the mechanism of action of the treatment across NDDs.
Behavior of KCNQ Channels in Neural Plasticity and Motor Disorders
There is a need to consolidate the updated findings regarding both the pharmacotherapeutic and pathological roles of KCNQ channels, especially regarding neural plasticity and motor disorders which have the largest body of literature on this channel.
Relapse in Dementia-related Psychosis and Clinical Decisions
A randomized medication withdrawal clinical trial design allows assessment of relapse risk after discontinuation and can provide initial information on longer-term safety of therapy for dementia-related psychosis.